Group 1 - The core viewpoint of the article highlights the recent performance of Kangtong Medical (301515), which closed at 25.92 yuan on February 9, 2026, with a 1.45% increase and a trading volume of 19,600 hands, resulting in a transaction amount of 50.62 million yuan [1] - The company reported a significant decline in its main revenue for the first three quarters of 2025, amounting to 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, down 150.92% [2] - In the third quarter of 2025, the company experienced a quarterly main revenue of 79.12 million yuan, which represents a year-on-year increase of 42.81%, although the net profit attributable to shareholders was still negative at -1.80 million yuan, a decline of 138.94% [2] Group 2 - The company's debt ratio stands at 40.94%, with investment income recorded at -179,400 yuan and financial expenses at 542,400 yuan, while the gross profit margin is reported at 22.45% [2] - The funding flow data indicates that on February 9, 2026, the main funds experienced a net outflow of 1.99 million yuan, accounting for 3.92% of the total transaction amount, while retail investors saw a net inflow of 5.16 million yuan, representing 10.19% of the total transaction amount [1]
股票行情快报：港通医疗（301515）2月9日主力资金净卖出198.62万元